

Fig. 1A

Fig. 1B




Fig. 2




Fig. 3






Fig. 4



Immobilized monoclonal antibody

Fig. 5



Title: ANTIBODY AGAINST FIBROBLAST
GROWTH FACTOR-23
Inventor(s): Yuji YAMAZAKI et al.
DOCKET NO.: 081356-0218

10/500296




Fig. 6

Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13





Fig. 14



Title: ANTIBODY AGAINST FIBROBLAST
GROWTH FACTOR-23
Inventor(s): Yuji YAMAZAKI et al.
DOCKET NO.: 081356-0218




Fig. 15

Fig. 16B




Fig. 16A




Fig. 17





Fig. 18A






Fig. 18B

Fig. 19B





Fig. 19A



Title: ANTIBODY AGAINST FIBROBLAST
GROWTH FACTOR-23
Inventor(s): Yuji YAMAZAKI et al.
DOCKET NO.: 081356-0218

Fig. 19C




Fig. 20




Fig. 21A

Group composition	Substance administered	Number of mice	Phosphate (mg/dL)	Calcium (mg/dL)	1,25(OH) ₂ D (pg/mL)
Group 1 :	PBS	4	8.95 +/- 0.31	9.41 +/- 0.20	118.1 +/- 8.1
Group 2 :	1D6A	4	.665 +/- 0.47 *	9.50 +/- 0.17	84.0 +/- 2.6 *
Group 3 :	2C3B	4	10.73 +/- 1.22	9.74 +/- 0.14	192.5 +/- 3.9 *
Group 4 :	3C1E	4	11.76 +/- 0.42 *	9.49 +/- 0.04	78.5 +/- 2.2 *
Group 5:	Anti-TPO antibody	4	8.93 +/- 0.41	9.41 +/- 0.08	147.9 +/- 3.8 *

Fig. 21B




Fig. 22B




Fig. 22A




Fig. 22D




Fig. 22C




Fig. 23

	Age	Gender	FGF-23(ng/L)	Mutation in PHEX gene
Case 1	3 months old	man	111.3	2071-1 g→a (Intron20)
	1 year old		380.3	
Case 2	38 years old	woman	39.0	2071-1 g→a (Intron20)
Case 3	5 years old	woman	55.7	849+1 g→a (Intron 7)
	13 years old		68.6	
Case 4	15 years old	woman	115.0	2071-2 a→g (Intron20)
Case 5	18 years old	woman	107.6	2071-2 a→g (Intron20)
Case 6	67 years old	woman	96.5	Q189X (Exon 5)

Fig. 24




Fig. 25A






Fig. 25B




Expression of

NaPi2a



Phosphate transport activity



WT				Hyp			
-	-	+	+	-	-	+	+
2C3B + 3C1E				1aOHase			
GAPDH				GAPDH			

Fig. 26




Fig. 27






Fig. 28




Title: ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR-23
Inventor(s): Yuji YAMAZAKI et al.
DOCKET NO.: 081356-0218

Fig. 29A

Serum osteocalcin concentration



Week 2 after ovariectomy



Week 4 after ovariectomy

Fig. 30A




Fig. 30B




Fig. 31A




Fig. 31B





Fig. 31C






Fig. 32

Fig. 33





Fig. 34



*p<0.001 vs Untreated/PBS before antibody administration
 #p=0.01 vs before antibody administration
 ##p<0.001 vs before antibody administration
 +p<0.05 vs FGF-23/PBS, 24 hours after antibody administration
 ++p<0.01 vs FGF-23/PBS, 24 hours after antibody administration
 +++p<0.001 vs FGF-23/PBS, 24 hours after antibody administration

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.